...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Technology in cancer research & treatment. >Detection and identification of potential biomarkers of non-small cell lung cancer.
【24h】

Detection and identification of potential biomarkers of non-small cell lung cancer.

机译：非小细胞肺癌潜在生物标志物的检测和鉴定。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to discover and identify potential protein biomarkers specific for non-small cell lung cancer (NSCLC). Two hundred and thirty five (235) Serum samples with 112 NSCLC and 123 controls were randomly divided into a training set and a blind testing set. Serum proteomic profiles were analyzed using surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI-TOF-MS). Candidate protein biomarkers were purified by high Performance Liquid Chromatography (HPLC) and identified by liquid chromatography tandem mass spectrometry (LC-MS/MS) and validated using ProteinChip immunoassays. A total of 3 peaks (m/z with 6628, 9191 and 11412 Da) were screened out by SVM to construct the classification model with the high discriminatory power in the training set. The sensitivity and specificity of the model were 96.56% and 94.79% respectively in the blind testing set. The candidate biomarker with m/z of 6628 Da was found down-regulated in NSCLC patients, and identified as apolipoprotein C-I. Another two candidate biomarkers (9191 and 11412 Da) were found up-regulated in serum of NSCLC patients and identified as haptoglobin alpha-1 chain and S100A4, respectively. We have identified a set of biomarkers that could discriminate NSCLC from non-cancer controls. An efficient strategy, including SELDI-TOF-MS analysis, HPLC purification, MALDI-TOF-MS trace and LC-MS/MS identification, has been proved successfully.
机译：这项研究的目的是发现和鉴定潜在的非小细胞肺癌（NSCLC）特有的蛋白质生物标志物。 235个（235）血清样本和112个NSCLC和123个对照被随机分为训练集和盲测集。使用表面增强的激光解吸/电离飞行时间质谱（SELDI-TOF-MS）分析血清蛋白质组学特征。候选蛋白质生物标志物通过高效液相色谱（HPLC）进行纯化，并通过液相色谱串联质谱法（LC-MS / MS）进行鉴定，并使用ProteinChip免疫测定法进行验证。通过SVM筛选出总共3个峰（m / z分别为6628、9191和11412 Da），以构建训练集中具有较高鉴别力的分类模型。在盲法试验中，模型的敏感性和特异性分别为96.56％和94.79％。在NSCLC患者中发现m / z为6628 Da的候选生物标记被下调，并被鉴定为载脂蛋白C-1。在NSCLC患者的血清中发现另外两个候选生物标志物（9191和11412 Da）上调，分别鉴定为触珠蛋白α-1链和S100A4。我们已经鉴定出一套可以将NSCLC与非癌症对照区分开的生物标记物。已经成功证明了包括SELDI-TOF-MS分析，HPLC纯化，MALDI-TOF-MS示踪和LC-MS / MS鉴定在内的有效策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号